RESEARCH: Validation of the Massachusetts General Hospital Antidepressant Treatment History Questionnaire (ATRQ)

Chandler, Gregory M.; Iosifescu, Dan V.; Pollack, Mark H.; Targum, Steven D.; Fava, Maurizio

doi:10.1111/j.1755-5949.2009.00102.x

Cited by 158Treatment of Major DepressionAnxiety, Depression, Psychometrics, Treatment, Cognitive ProcessesElectroconvulsive Therapy Studies

RESEARCH: Validation of the Massachusetts General Hospital Antidepressant Treatment History Questionnaire (ATRQ)

Open access

Chandler, Gregory M., Iosifescu, Dan V., Pollack, Mark H., Targum, Steven D., Fava, Maurizio·2010·CNS Neuroscience & Therapeutics

DOI 10.1111/j.1755-5949.2009.00102.xPMC PMC6493891

Open this paper in CoChat — free account Open PDF

Abstract

The low rate of response to antidepressants in treatment resistant depression (TRD) justifies studies of next‐step therapies following a treatment failure. In TRD clinical trials, it is important to verify the accurate diagnosis of treatment resistance for all enrolled subjects using a reliable and valid instrument. Self‐rated scales can reduce the impact of investigator bias and reduce the time burden for clinical researchers. The Massachusetts General Hospital (MGH) Antidepressant Treatment Response Questionnaire (ATRQ) is a self‐rated scale used to determine treatment resistance in major depressive disorder (MDD). The ADAPT‐A study is a multi‐center double‐blind, placebo‐controlled study of low‐dose aripiprazole adjunctive to ADT among outpatients with TRD. At the screening assessment, potential subjects completed the MGH ATRQ. The ADAPT‐A medical monitors subsequently performed remote patient interviews and obtained detailed medication histories. The data obtained from the MGH ATRQ and by the medical monitors were compared for congruency. Of the 186 patients enrolled by the local sites, no subjects deemed treatment resistant by the MGH ATRQ were found to be nonresistant by the medical monitors. In 76.3% (n = 142) of the subjects, the number of failed adequate antidepressant trials reported by the MGH ATRQ was concordant with the data collected by medical monitors. In 16.1% (n = 30) of all cases, the medical monitors found a greater number of failed trials; in 7.5% (n = 14) of cases, the medical monitors found fewer failed medication trials. The discrepancy was by more than one medication trial in only 4.0% (n = 7) of cases. We found the MGH ATRQ to be relatively concordant in its assessment of treatment resistance in depression compared with independent clinical researchers. Although the MGH ATRQ tended to underreport the number of unsuccessful treatment trials relative to the clinical interviews, its accuracy in cases it detected was confirmed by raters.

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

Integrity signals

Registry

Crossref · 10.1111/j.1755-5949.2009.00102.x

Cites

14 of 14 references verified0 citation errors · 0 not checkable

Statistics

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Other instruments that capture and record current and prior antidepressant regimens are the self-rated Massachusetts General Hospital Antidepressant Treatment Response Questionnaire (ATRQ) and the Maudsley Treatment Inventory.
“Other instruments that capture and re- cord current and prior antidepressant regimens are the self- rated Massachusetts General Hos pital Antidepressant Treatment Response Questionnaire (ATRQ) 166 and the Maudsley Treatment Inventory 56 .”
From Treatment‐resistant depression: definition, prevalence, detection, management, and investigational interventions (2023) · cites this paper as [166]

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Evaluation of outcomes with citalopram for depression using measurement-based care in STAR*D: implications for clinical practice
Trivedi, M. H., Rush, A. J., Wisniewski, S. R., Nierenberg, A. A., Warden, D., Ritz, L., Norquist, G., Howland, R. H., Lebowitz, B., McGrath, P. J., et al. (2006) · American Journal of Psychiatry · doi:10.1176/appi.ajp.163.1.28 · Cited by 3,879 · see citing works
Self-citation
Diagnosis and definition of treatment-resistant depression
Fava, M. (2003) · Biological Psychiatry · doi:10.1016/s0006-3223(03)00231-2 · Cited by 1,380 · see citing works
Self-citation
Distributed Disturbances in Brain Structure and Function in Schizophrenia
Lewis, D. A. (2000) · American Journal of Psychiatry · doi:10.1176/ajp.157.1.1 · Cited by 971 · see citing works
DEFINITION AND EPIDEMIOLOGY OF TREATMENT-RESISTANT DEPRESSION
Fava, M., & Davidson, K. G. (1996) · Psychiatric Clinics of North America · doi:10.1016/s0193-953x(05)70283-5 · Cited by 797 · see citing works
Self-citation
Untitled work
(2001) · PubMed · Cited by 780 · see citing works
The Efficacy and Safety of Aripiprazole as Adjunctive Therapy in Major Depressive Disorder: A Second Multicenter, Randomized, Double-Blind, Placebo-Controlled Study
Marcus, R. N., McQuade, R. D., Carson, W. H., Hennicken, D., Fava, M., Simon, J. S., Trivedi, M. H., Thase, M. E., & Berman, R. M. (2008) · Journal of Clinical Psychopharmacology · doi:10.1097/jcp.0b013e31816774f9 · Cited by 518 · see citing works
Self-citation
Practice guideline for the treatment of patients with major depressive disorder (revision). American Psychiatric Association.
(2000) · PubMed · Cited by 509 · see citing works
The Efficacy and Safety of Aripiprazole as Adjunctive Therapy in Major Depressive Disorder: A Multicenter, Randomized, Double-Blind, Placebo-Controlled Study
Berman, R. M., Marcus, R. N., Swanink, R., McQuade, R. D., Carson, W. H., Corey-Lisle, P. K., & Khan, A. (2007) · The Journal of Clinical Psychiatry · doi:10.4088/jcp.v68n0604 · Cited by 409 · see citing works
STAR*D: What Have We Learned?
Rush, A. J. (2007) · American Journal of Psychiatry · doi:10.1176/ajp.2007.164.2.201 · Cited by 353 · see citing works
Nonfinancial Conflicts of Interest in Research
Levinsky, N. G. (2002) · New England Journal of Medicine · doi:10.1056/nejmsb020853 · Cited by 169 · see citing works
Efficacy and Safety of Mirtazapine in Major Depressive Disorder Patients After SSRI Treatment Failure
D, M. F. M., Dünner, D. L., Greist, J. H., Preskorn, S., Trivedi, M. H., Zajecka, J., & Cohen, M. (2001) · The Journal of Clinical Psychiatry · doi:10.4088/jcp.v62n0603 · Cited by 94 · see citing works
Refractory Depression
Rabins, P. V. (1992) · American Journal of Psychiatry · doi:10.1176/ajp.149.7.978 · Cited by 39 · see citing works
The Efficacy and Tolerability of Duloxetine in the Treatment of Anxious Versus Non-Anxious Depression: A Post-Hoc Analysis of an Open-Label Outpatient Study
Fava, M., Martinez, J. M., Greist, J., Marangell, L. B., Brown, E., Chen, L., & Wohlreich, M. M. (2007) · Annals of Clinical Psychiatry · doi:10.1080/10401230701465178 · Cited by 25 · see citing works
Immediate Switching of Antidepressant Therapy: Results from a Clinical Trial of Duloxetine
Wohlreich, M. M., Mallinckrodt, C. H., Watkin, J. G., wilson, M., Greist, J., Delgado, P. L., & D, M. F. M. (2005) · Annals of Clinical Psychiatry · doi:10.1080/10401230500296402 · Cited by 21 · see citing works

Flagged first, then by citations

Sorted by citations

Single-Dose Psilocybin for a Treatment-Resistant Episode of Major Depression
Goodwin, G. M., Aaronson, S. T., Alvarez, O., Arden, P. C., Baker, A., Bennett, J. C., Bird, C., Blom, R. E., Brennan, C., Brusch, D., et al. (2022) · New England Journal of Medicine · doi:10.1056/nejmoa2206443 · Cited by 1,167 · see citing works
Efficacy and Safety of Flexibly Dosed Esketamine Nasal Spray Combined With a Newly Initiated Oral Antidepressant in Treatment-Resistant Depression: A Randomized Double-Blind Active-Controlled Study
Popova, V., Daly, E. J., Trivedi, M., Cooper, K., Lane, R., Lim, P., Mazzucco, C., Hough, D., Thase, M. E., Shelton, R. C., et al. (2019) · American Journal of Psychiatry · doi:10.1176/appi.ajp.2019.19020172 · Cited by 904 · see citing works
Treatment‐resistant depression: definition, prevalence, detection, management, and investigational interventions
McIntyre, R. S., Alsuwaidan, M., Baune, B. T., Berk, M., Demyttenaere, K., Goldberg, J. F., Gorwood, P., Ho, R., Kasper, S., Kennedy, S. H., et al. (2023) · World Psychiatry · doi:10.1002/wps.21120 · Cited by 836 · see citing works
Efficacy and Safety of Intranasal Esketamine Adjunctive to Oral Antidepressant Therapy in Treatment-Resistant Depression: A Randomized Clinical Trial
Daly, E. J., Singh, J. B., Fedgchin, M., Cooper, K., Lim, P., Shelton, R. C., Thase, M. E., Winokur, A., Van Nueten, L., Manji, H., et al. (2018) · JAMA Psychiatry · doi:10.1001/jamapsychiatry.2017.3739 · Cited by 718 · see citing works
Efficacy and Safety of Fixed-Dose Esketamine Nasal Spray Combined With a New Oral Antidepressant in Treatment-Resistant Depression: Results of a Randomized, Double-Blind, Active-Controlled Study (TRANSFORM-1)
Fedgchin, M., Trivedi, M., Daly, E. J., Melkote, R., Lane, R., Lim, P., Vitagliano, D., Blier, P., Fava, M., Liebowitz, M., et al. (2019) · International Journal of Neuropsychopharmacology · doi:10.1093/ijnp/pyz039 · Cited by 606 · see citing works
Self-citation
A double-blind, randomized, placebo-controlled, dose-frequency study of intravenous ketamine in patients with treatment-resistant depression.
Singh, J. B., Fedgchin, M., Daly, E. J., De Boer, P., Cooper, K., Lim, P., Pinter, C., Murrough, J. W., Sanacora, G., Shelton, R. C., et al. (2016) · American Journal of Psychiatry · doi:10.1176/appi.ajp.2016.16010037 · Cited by 525 · see citing works
Attenuation of Antidepressant Effects of Ketamine by Opioid Receptor Antagonism
Williams, N. R., Heifets, B. D., Blasey, C., Sudheimer, K., Pannu, J., Pankow, H., Hawkins, J., Birnbaum, J., Lyons, D. M., Rodriguez, C. I., et al. (2018) · American Journal of Psychiatry · doi:10.1176/appi.ajp.2018.18020138 · Cited by 519 · see citing works
Efficacy and Safety of Esketamine Nasal Spray Plus an Oral Antidepressant in Elderly Patients With Treatment-Resistant Depression—TRANSFORM-3
Ochs-Ross, R., Daly, E. J., Zhang, Y., Lane, R., Lim, P., Morrison, R. L., Hough, D., Manji, H., Drevets, W. C., Sanacora, G., et al. (2020) · The American Journal of Geriatric Psychiatry · doi:10.1016/j.jagp.2019.10.008 · Cited by 481 · see citing works
Establishing moderators and biosignatures of antidepressant response in clinical care (EMBARC): Rationale and design
Trivedi, M. H., McGrath, P. J., Fava, M., Parsey, R. V., Kurian, B. T., Phillips, M. L., Oquendo, M. A., Bruder, G., Pizzagalli, D., Toups, M., et al. (2016) · Journal of Psychiatric Research · doi:10.1016/j.jpsychires.2016.03.001 · Cited by 286 · see citing works
Self-citation
Antidepressant treatment resistance is associated with increased inflammatory markers in patients with major depressive disorder
Haroon, E., Daguanno, A. W., Woolwine, B. J., Goldsmith, D. R., Baer, W. M., Wommack, E. C., Felger, J. C., & Miller, A. H. (2018) · Psychoneuroendocrinology · doi:10.1016/j.psyneuen.2018.05.026 · Cited by 291 · see citing works
Conceptual convergence: increased inflammation is associated with increased basal ganglia glutamate in patients with major depression
Haroon, E., Fleischer, C. C., Felger, J. C., Chen, X., Woolwine, B. J., Patel, T., Hu, X. P., & Miller, A. H. (2016) · Molecular Psychiatry · doi:10.1038/mp.2015.206 · Cited by 250 · see citing works
Opioid Modulation With Buprenorphine/Samidorphan as Adjunctive Treatment for Inadequate Response to Antidepressants: A Randomized Double-Blind Placebo-Controlled Trial
Fava, M., Memisoglu, A., Thase, M. E., Bodkin, J. A., Trivedi, M. H., de Somer, M., Du, Y., Leigh-Pemberton, R., DiPetrillo, L., Silverman, B., et al. (2016) · American Journal of Psychiatry · doi:10.1176/appi.ajp.2015.15070921 · Cited by 232 · see citing works
A Delphi-method-based consensus guideline for definition of treatment-resistant depression for clinical trials
Sforzini, L., Worrell, C., Kose, M., Anderson, I. M., Aouizerate, B., Arolt, V., Bauer, M., Baune, B. T., Blier, P., Cleare, A. J., et al. (2022) · Molecular Psychiatry · doi:10.1038/s41380-021-01381-x · Cited by 214 · see citing works
Repeat-dose ketamine augmentation for treatment-resistant depression with chronic suicidal ideation: A randomized, double blind, placebo controlled trial
Ionescu, D. F., Bentley, K. H., Eikermann, M., Taylor, N., Akeju, O., Swee, M. B., Pavone, K. J., Petrie, S. R., Dording, C., Mischoulon, D., et al. (2019) · Journal of Affective Disorders · doi:10.1016/j.jad.2018.09.037 · Cited by 179 · see citing works
Self-citation
Efficacy and Safety of Adjunctive Brexpiprazole 2 mg in Major Depressive Disorder: A Phase 3, Randomized, Placebo-Controlled Study in Patients With Inadequate Response to Antidepressants
Thase, M. E., Youakim, J. M., Skuban, A., Hobart, M., Augustine, C., Zhang, P., McQuade, R. D., Carson, W. H., Nyilas, M., Sanchez, R., et al. (2015) · The Journal of Clinical Psychiatry · doi:10.4088/jcp.14m09688 · Cited by 182 · see citing works
Pilot Randomized Controlled Trial of Titrated Subcutaneous Ketamine in Older Patients with Treatment-Resistant Depression
George, D., Gálvez, V., Martin, D., Kumar, D., Leyden, J., Hadzi-Pavlovic, D., Harper, S., Brodaty, H., Glue, P., Taylor, R., et al. (2017) · The American Journal of Geriatric Psychiatry · doi:10.1016/j.jagp.2017.06.007 · Cited by 149 · see citing works
A Double-Blind, Placebo-Controlled Study of Aripiprazole Adjunctive to Antidepressant Therapy among Depressed Outpatients with Inadequate Response to Prior Antidepressant Therapy (ADAPT-A Study)
Fava, M., Mischoulon, D., Iosifescu, D., Witte, J., Pencina, M., Flynn, M., Harper, L., Levy, M., Rickels, K., & Pollack, M. (2012) · Psychotherapy and Psychosomatics · doi:10.1159/000332050 · Cited by 141 · see citing works
Self-citation
Efficacy and Safety of Basimglurant as Adjunctive Therapy for Major Depression: A Randomized Clinical Trial
Quiroz, J. A., Tamburri, P., Deptula, D., Banken, L., Beyer, U., Rabbia, M., Parkar, N., Fontoura, P., & Santarelli, L. (2016) · JAMA Psychiatry · doi:10.1001/jamapsychiatry.2016.0838 · Cited by 133 · see citing works
Difficult-to-treat depression: A clinical and research roadmap for when remission is elusive
Rush, A. J., Aaronson, S. T., & Demyttenaere, K. (2019) · Australian & New Zealand Journal of Psychiatry · doi:10.1177/0004867418808585 · Cited by 120 · see citing works
Single-Dose Synthetic Psilocybin With Psychotherapy for Treatment-Resistant Bipolar Type II Major Depressive Episodes: A Nonrandomized Open-Label Trial
Aaronson, S. T., van der Vaart, A., Miller, T., LaPratt, J., Swartz, K., Shoultz, A., Lauterbach, M., Sackeim, H. A., & Suppes, T. (2024) · JAMA Psychiatry · doi:10.1001/jamapsychiatry.2023.4685 · Cited by 114 · see citing works
Cognitive Behavioral Therapy to Sustain the Antidepressant Effects of Ketamine in Treatment-Resistant Depression: A Randomized Clinical Trial
Wilkinson, S. T., Rhee, T. G., Joormann, J., Webler, R., Ortiz Lopez, M., Kitay, B., Fasula, M., Elder, C., Fenton, L., & Sanacora, G. (2021) · Psychotherapy and Psychosomatics · doi:10.1159/000517074 · Cited by 108 · see citing works
Clinical research challenges posed by difficult-to-treat depression.
Rush, A. J., Sackeim, H. A., Conway, C. R., Bunker, M. T., Hollon, S. D., Demyttenaere, K., Young, A. H., Aaronson, S. T., Dibué, M., Thase, M. E., et al. (2022) · Psychological Medicine · doi:10.1017/s0033291721004943 · Cited by 89 · see citing works
A Novel, Brief, Fully Automated Intervention to Extend the Antidepressant Effect of a Single Ketamine Infusion: A Randomized Clinical Trial
Price, R. B., Spotts, C., Panny, B., Griffo, A., Degutis, M., Cruz, N., Bell, E., Do-Nguyen, K., Wallace, M. L., Mathew, S. J., et al. (2022) · American Journal of Psychiatry · doi:10.1176/appi.ajp.20220216 · Cited by 85 · see citing works
CLINICAL OUTCOMES IN MEASUREMENT-BASED TREATMENT (COMET): A TRIAL OF DEPRESSION MONITORING AND FEEDBACK TO PRIMARY CARE PHYSICIANS: Research Article: COMET for Depression
Yeung, A. S., Jing, Y., Brenneman, S. K., Chang, T. E., Baer, L., Hebden, T., Kalsekar, I., McQuade, R. D., Kurlander, J., Siebenaler, J., et al. (2012) · Depression and Anxiety · doi:10.1002/da.21983 · Cited by 74 · see citing works
Rapid Neuroplasticity Changes and Response to Intravenous Ketamine: A Randomized Controlled Trial in Treatment-Resistant Depression
Kopelman, J., Keller, T. A., Panny, B., Griffo, A., Degutis, M., Spotts, C., Cruz, N., Bell, E., Do-Nguyen, K., Wallace, M. L., et al. (2023) · Translational Psychiatry · doi:10.1038/s41398-023-02451-0 · Cited by 60 · see citing works
Prospective Service Use and Health Care Costs of Medicaid Beneficiaries with Treatment-Resistant Depression
Olfson, M., Amos, T. B., Benson, C., McRae, J., & Marcus, S. C. (2018) · Journal of Managed Care & Specialty Pharmacy · doi:10.18553/jmcp.2018.24.3.226 · Cited by 48 · see citing works
Tachyphylaxis in major depressive disorder: A review of the current state of research
Kinrys, G., Gold, A. K., Pisano, V. D., Freeman, M. P., Papakostas, G. I., Mischoulon, D., Nierenberg, A. A., & Fava, M. (2019) · Journal of Affective Disorders · doi:10.1016/j.jad.2018.10.357 · Cited by 45 · see citing works
Effects of Open-Label, Adjunctive Ganaxolone on Persistent Depression Despite Adequate Antidepressant Treatment in Postmenopausal Women: A Pilot Study
Dichtel, L. E., Nyer, M., Dording, C., Fisher, L. B., Cusin, C., Shapero, B. G., Pedrelli, P., Kimball, A. S., Rao, E. M., Mischoulon, D., et al. (2020) · The Journal of Clinical Psychiatry · doi:10.4088/jcp.19m12887 · Cited by 40 · see citing works
Self-citation
Brexpiprazole as adjunctive treatment of major depressive disorder with anxious distress: results from a post-hoc analysis of two randomised controlled trials
McIntyre, R. S., Weiller, E., Zhang, P., & Weiss, C. (2016) · Journal of Affective Disorders · doi:10.1016/j.jad.2016.05.013 · Cited by 36 · see citing works
Efficacy and safety of TS-121, a novel vasopressin V1B receptor antagonist, as adjunctive treatment for patients with major depressive disorder: A randomized, double-blind, placebo-controlled study
Kamiya, M., Sabia, H. D., Marella, J., Fava, M., Nemeroff, C. B., Umeuchi, H., Iijima, M., Chaki, S., & Nishino, I. (2020) · Journal of Psychiatric Research · doi:10.1016/j.jpsychires.2020.05.017 · Cited by 28 · see citing works
Self-citation
Adjunctive Brexpiprazole in Patients With Major Depressive Disorder and Irritability: An Exploratory Study
Fava, M., Ménard, F., Davidsen, C. K., & Baker, R. A. (2016) · The Journal of Clinical Psychiatry · doi:10.4088/jcp.15m10470 · Cited by 23 · see citing works
Self-citation
Adjunctive brexpiprazole for elderly patients with major depressive disorder: An open‐label, long‐term safety and tolerability study
Lepola, U., Hefting, N., Zhang, D., & Hobart, M. (2018) · International Journal of Geriatric Psychiatry · doi:10.1002/gps.4952 · Cited by 15 · see citing works
Ziprasidone augmentation for anxious depression
Ionescu, D. F., Shelton, R. C., Baer, L., Meade, K. H., Swee, M. B., Fava, M., & Papakostas, G. I. (2016) · International Clinical Psychopharmacology · doi:10.1097/yic.0000000000000133 · Cited by 10 · see citing works
Self-citation

Susquehanna Chorale Spring Concert "Roots and Wings"
Hawkins, D. (2017)
Personality correlates and utilitarian judgments in the everyday context: Psychopathic traits and differential effects of empathy, social dominance orientation, and dehumanization beliefs
Takamatsu, R. (2019) · Personality and Individual Differences · doi:10.1016/j.paid.2019.03.029 · Cited by 22 · see citing works
Amount of altruistic punishment accounts for subsequent emotional gratification in participants with primary psychopathy
Masui, K., Iriguchi, S., Nomura, M., & Ura, M. (2011) · Personality and Individual Differences · doi:10.1016/j.paid.2011.07.006 · Cited by 14 · see citing works
The Information Used to Judge Supportiveness Depends on Whether the Judgment Reflects the Personality of Perceivers, the Objective Characteristics of Targets, or their Unique Relationships
Lakey, B., Lutz, C. J., & Scoboria, A. (2004) · Journal of Social and Clinical Psychology · doi:10.1521/jscp.23.6.817.54806 · Cited by 14 · see citing works
The Mental Representations Of High And Low Entitativity Groups
Johnson, A. L., & Queller, S. (2003) · Social Cognition · doi:10.1521/soco.21.2.101.21316 · Cited by 13 · see citing works

Authors: Chandler, G. M., Iosifescu, D. V., Pollack, M. H., Targum, S. D., & Fava, M.
Affiliations: Massachusetts General Hospital (US)
Corresponding author: Chandler, Gregory M.
ORCID: Chandler, Gregory M.
Iosifescu, Dan V.
Pollack, Mark H.
Targum, Steven D.
Venue: CNS Neuroscience & Therapeutics
Publisher: Wiley
Published: 2010-09-03
Volume: 16
Issue: 5
Pages: 322-325
ISSN: 1755-5930 (ISSN-L)
1755-5949
DOI: 10.1111/j.1755-5949.2009.00102.x
PMC: PMC6493891
OpenAlex: W2111663098
Cited by: 158
References: 14
Citations by year: 2026: 12 · 2025: 12 · 2024: 12 · 2023: 10 · 2022: 10 · 2021: 11 · 2020: 17 · 2019: 12 · 2018: 15 · 2017: 10 · 2016: 13 · 2015: 10 · 2014: 3 · 2013: 4 · 2012: 5
FWCI: 1.68
Type: journal article
Language: en
Open access: bronze
doi.org
Licence: onlinelibrary.wiley.com/termsAndConditions#vor (vor)
Locations: CNS Neuroscience & Therapeutics (publishedVersion)
Europe PMC (PubMed Central) (publishedVersion)
PubMed Central (publishedVersion)
PubMed (publishedVersion)
Topics: Health Sciences › Medicine › Pharmacology › Treatment of Major Depression
Social Sciences › Psychology › Experimental and Cognitive Psychology › Anxiety, Depression, Psychometrics, Treatment, Cognitive Processes
Health Sciences › Medicine › Psychiatry and Mental health › Electroconvulsive Therapy Studies
Keywords: treatment-resistant depression, major depressive disorder
MeSH terms: Aripiprazole, Depression, Double-Blind Method, Female, Humans, Male, Massachusetts, Piperazines, Surveys and Questionnaires, Antipsychotic Agents, Reproducibility of Results, Quinolones, Self Report

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

RESEARCH: Validation of the Massachusetts General Hospital Antidepressant Treatment History Questionnaire (ATRQ)

Abstract

Integrity signals

Claims the paper makes

Claims other papers make about this one

Self-check

Cites

Cited by

Related

Record

About these checks